CAR T-cell therapy for SLE in children
On March 11, 2024, Seattle Children’s Hospital (Seattle, WA, USA) announced that it had received approval from the US Food and Drug Administration for a clinical trial of chimeric antigen receptor (CAR) T cells in children with systemic lupus erythematosus (SLE). The study will involve 12 individuals younger than 18 years with refractory SLE. They will each be given a single infusion of CAR T cells. The principal investigator is Shaun Jackson, Attending Physician at Seattle Children’s Nephrology and Rheumatology Program and Associate Professor of Paediatrics at the University of Washington (Seattle, WA, USA).